Sugi Predict

Sugi Predict / Targets / RPS6KA5

RPS6KA5

Ribosomal protein S6 kinase alpha-5 · O75582 · RPS6KA5 on Sugi Atlas →

51,329 patent compounds predicted against RPS6KA5, 37,748 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL144979 SCHEMBL144979 0.56 4/20
Linifanib Linifanib (SCHEMBL93804) 1.00 3/20
SCHEMBL144651 SCHEMBL144651 0.67 3/20
SCHEMBL144378 SCHEMBL144378 0.66 3/20
SCHEMBL142020 SCHEMBL142020 0.65 3/20
SCHEMBL144118 SCHEMBL144118 0.61 3/20
SCHEMBL144615 SCHEMBL144615 0.61 3/20
SCHEMBL143818 SCHEMBL143818 0.61 3/20
SCHEMBL143827 SCHEMBL143827 0.59 3/20
SCHEMBL144183 SCHEMBL144183 0.58 3/20
SCHEMBL140610 SCHEMBL140610 0.56 3/20
SCHEMBL143148 SCHEMBL143148 0.56 3/20
SCHEMBL65790 SCHEMBL65790 0.52 3/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL58421) 0.52 3/20
SCHEMBL90887 SCHEMBL90887 0.49 3/20
SCHEMBL90935 SCHEMBL90935 0.49 3/20
Rosoxacin Rosoxacin (SCHEMBL135645) 0.48 3/20
SCHEMBL83395 SCHEMBL83395 0.46 3/20
SCHEMBL123581 SCHEMBL123581 0.34 3/20
Sunitinib Sunitinib (SCHEMBL8081) 1.00 2/20

Clinical trials — most relevant to RPS6KA5 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer PHASE1/PHASE2COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery PHASE2COMPLETED
Biased GRK Signaling Via β2-Adrenergic Receptors in Human Skeletal Muscle PHASE2NOT_YET_RECRUITING
Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma PHASE1/PHASE2COMPLETED
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients PHASE1/PHASE2COMPLETED
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety PHASE2COMPLETED
A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis PHASE1/PHASE2COMPLETED
Phase II Lung Metcore - Preoperative Metformin for Lung Cancer PHASE2COMPLETED
Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI PHASE2COMPLETED
Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC) PHASE1/PHASE2COMPLETED
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer PHASE2COMPLETED
Neoadjuvant CCI-779 Followed By Radical Prostatectomy in Treating Patients With Newly Diagnosed Prostate Cancer Who Have a High Risk of Relapse PHASE2COMPLETED
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment PHASE1COMPLETED
Therapeutic RSK1 Targeting in Myelofibrosis PHASE1RECRUITING
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors PHASE1ACTIVE_NOT_RECRUITING
Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors PHASE1COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer EARLY_PHASE1COMPLETED
Effect of Branched Chain Amino Acids on Muscle nanCOMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED
Testing of Micellar Casein, Blended Micellar Casein and Native Whey nanCOMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory nanCOMPLETED
Protein Intake and Step Reduction in Older Adults nanCOMPLETED
Impacts of Mechanistic Target of Rapamycin (mTOR) Inhibition on Aged Human Muscle (Rapamune) nanRECRUITING
The Effects of Whey vs. Collagen on MPS nanCOMPLETED
Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation After Liver Transplantation nanCOMPLETED
NK Cell Deregulation in HBV Patients nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a RPS6KA5 binder may also engage these)

ProteinNameSimilarity
Q5R4K3 — 1.000 Q5R4K3 →
Q5F3L1 — 1.000 Q5F3L1 →
Q8C050 — 1.000 Q8C050 →
Q6PFQ0 — 1.000 Q6PFQ0 →
RPS6KA1 Ribosomal protein S6 kinase alpha-1 1.000 landscape →
P10665 — 0.997 P10665 →
Q63531 — 0.996 Q63531 →
P18654 — 0.996 P18654 →
RPS6KA3 Ribosomal protein S6 kinase alpha-3 0.995 landscape →
Q7TPS0 — 0.995 Q7TPS0 →
P18652 — 0.994 P18652 →
RPS6KA6 Ribosomal protein S6 kinase alpha-6 0.994 landscape →
P11730 — 0.993 P11730 →
P13234 — 0.993 P13234 →
RPS6KA2 Ribosomal protein S6 kinase alpha-2 0.993 landscape →
Q6U1I9 — 0.993 Q6U1I9 →
STK32A Serine/threonine-protein kinase 32A 0.992 landscape →
Q8BHI9 — 0.992 Q8BHI9 →
Q9NBK5 — 0.992 Q9NBK5 →
Q6GPN6 — 0.992 Q6GPN6 →
PRKCD Protein kinase C delta type 0.992 landscape →
P18653 — 0.992 P18653 →
P09215 — 0.992 P09215 →
Q5RD00 — 0.991 Q5RD00 →
Q91VJ4 — 0.991 Q91VJ4 →
A8XJQ6 — 0.991 A8XJQ6 →
Q9WVC6 — 0.991 Q9WVC6 →
Q5R8M1 — 0.991 Q5R8M1 →
Q9WUT3 — 0.991 Q9WUT3 →
CAMK2D Calcium/calmodulin-dependent protein kinase type II subunit delta 0.991 landscape →